Monday, 18 October 2021

Bharat Biotech says Covaxin to get Approval from WHO at the earliest

Bharat Biotech says Covaxin to get Approval from WHO at the earliest

Bharat Biotech said the review process for the Covaxin vaccine has commenced with the expectation that it will receive an emergency use listing from the World Health Organisation at the earliest.

With a review process of Covaxin, the indigenous vaccine against COVID-19, commencing at the World Health Organisation (WHO), the Hyderabad-based Bharat Biotech on Monday said it expects to receive emergency use listing (EUL) from the global body at the earliest.
"All documents required for emergency use listing (EUL) of Covaxin have been submitted to WHO as of July 9. The review process has now commenced with the expectation that we will receive EUL from the WHO at the earliest," said Dr. Krishna Ella, Chairman and Managing Director, Bharat Biotech.

World Health Organisation pre-qualification, or a EUL, is compulsory for vaccine companies to supply vaccines for global amenities such as Covax or international supply.

Bharat Biotech says Covaxin to get Approval from WHO at the earliestgetty images

Read More: Covishield, Sputnik V cost cheaper than Covaxin

The WHO has approved Pfizer-BioNTech, AstraZeneca- SK Bio/SII, Johnson & Johnson Janssen, Moderna, and Sinopharm for emergency use.

The indigenous vaccine showed 63.6 percent efficacy against the Delta variant of Covid-19, which has spread in many other countries. Covaxin demonstrated 93.4 percent efficacy against severe symptomatic Covid-19 and 63.6 percent against asymptomatic Covid-19.

The test was conducted on 25,800 subjects, and the data submitted to the Subject Expert Committee (SEC) showed the vaccine was "well-tolerated."Bharat Biotech says Covaxin to get Approval from WHO at the earliest.

Bharat Biotech said the review process for the Covaxin vaccine has commenced with the expectation that it will receive an emergency use listing from the World Health Organisation at the earliest.

With a review process of Covaxin, the indigenous vaccine against COVID-19, commencing at the World Health Organisation (WHO), the Hyderabad-based Bharat Biotech on Monday said it expects to receive emergency use listing (EUL) from the global body at the earliest.

Dr. Krishna Ella, Chairman and Managing Director, Bharat Biotech said 

"All documents required for emergency use listing (EUL) of Covaxin have been submitted to WHO as of July 9. The review process has now commenced with the expectation that we will receive EUL from the WHO at the earliest," 

World Health Organisation pre-qualification, or a EUL, is compulsory for vaccine companies to supply vaccines for global amenities such as Covax or international supply.

The WHO has approved Pfizer-BioNTech, AstraZeneca- SK Bio/SII, Johnson & Johnson Janssen, Moderna, and Sinopharm for emergency use.

The indigenous vaccine showed 63.6 percent efficacy against the Delta variant of Covid-19, which has spread in many other countries. Covaxin demonstrated 93.4 percent efficacy against severe symptomatic Covid-19 and 63.6 percent against asymptomatic Covid-19.

The test was conducted on 25,800 subjects, and the data submitted to the Subject Expert Committee (SEC) showed the vaccine was "well-tolerated."

Follow Us

Popular Post